Company_Context
Healthcare
Surgical & Medical Instruments & Apparatus
Institutional analysis of internal capital flows based on SEC Form 4 filings.
Signal_Window
Headline metrics use exact calendar-day windows.
22 directional transactions in 365D
Code P purchases and code S sales are measured from 2025.08.29 — 2026.08.28.
-$2.9M
Open-market buys minus sales2026.08.20
Latest available filing26
Reporting entities in windowNo 365D buyer
No open-market buys in 365DPolen Thomas E Jr
$1.2MAnalysis of eligible SEC Form 4 activity for BDX indicates a bearish 365-day signal. The selected window contains transactions from 26 distinct reporting insiders, with aggregate nominal activity of $23.73M.
Open-market purchases minus open-market sales produce a negative net flow of $2.92M. Compensation-related awards and option exercises represent more nominal activity than directional open-market trades, so the signal should be interpreted cautiously.
The largest open-market sale in the selected window was attributed to Polen Thomas E Jr (Director, Chairman, CEO and President). Form 4 activity provides useful ownership context, but it should not be treated as a standalone prediction of future price performance.
Enriched_Research_Context
These indicators use normalized SEC roles, issuer metadata, cluster detection and post-filing market prices already calculated by the data pipeline.
Healthcare
Surgical & Medical Instruments & Apparatus
0
Clustered open-market purchase records in the recent filing sample.
Recent_Filing_History
This table shows recent filing history and is not restricted by the selected 365D headline signal window.
No eligible open-market purchases were reported for BDX during the last 365 calendar days.
During the last 365 calendar days, eligible open-market sales total $2.92M. Polen Thomas E Jr recorded the largest aggregate selling volume.
The 365-day open-market signal is BEARISH, with net flow of $2.92M across 26 reporting insiders in the selected window.
Garrison Michael David
OPEN_MARKET_SALEEVP & Pres Med.Essntl&BioPharm · 2026.06.10
30D
+2.8%
90D
PENDING
180D
PENDING
Performance uses the latest matured open-market record in this sample. It describes subsequent market movement and does not imply that the filing caused the price change.